$LLY · Eli Lilly and Company

Eli Lilly and Company filed its Form 10-Q quarterly report for the third quarter ended September 30, 2026. The filing covers the three-month and nine-month periods ended September 30, 2026, and contains unaudited financial statements and related disclosures. The excerpt includes detailed data tagging for revenue by product and geography, referencing products such as Mounjaro, Zepbound, Jardiance, Trulicity, Verzenio, and Taltz, as well as category groupings for cardiometabolic health, oncology, immunology, and neuroscience.

The provided text does not include the actual dollar amounts or management's narrative discussion, so the specific financial results cannot be stated from this excerpt. The filing itself is the company's standard quarterly disclosure of financial position, results of operations, and notes for the period.